A Phase 2 interventional study of Placebo and Baricitinib in Psoriasis, Skin Diseases and Skin Diseases, Papulosquamous, sponsored by Eli Lilly and Company. Completed at 35 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-27.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 2, and was the 4th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 271 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
You must not have received a topical Ps treatment within 2 weeks prior to entry into the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
Drug: Placebo
Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
Drug: Baricitinib
Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
Drug: Baricitinib
Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
Drug: Baricitinib
Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
Drug: Baricitinib
Administered orally
Administered orally
Also known as: LY3009104, INCB028050
Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.
Time frame: Week 12
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.
Time frame: Week 12
Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.
Time frame: Week 24
Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.
Time frame: Week 92
Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.
Time frame: Baseline Part A, Week 12
Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.
Time frame: Baseline Part A, Week 24
Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.
Time frame: Baseline Part D, Week 92
Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline Part A, Week 12
Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.
Time frame: Baseline Part A, Week 24
Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.
Time frame: Baseline Part D, Week 92
Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline Part A, Week 12
Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Baseline Part A, Week 24
Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Baseline Part D, Week 92
Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12
The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline Part A, Week 12
Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24
The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.
Time frame: Baseline Part A, Week 24
Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92
The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.
Time frame: Baseline Part D, Week 92
Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores
The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline Part A, Week 12
Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores
The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.
Time frame: Baseline Part A, Week 24
Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores
The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.
Time frame: Baseline Part D, Week 92
Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C
Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score \>125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.
Time frame: Week 40
Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib
Time frame: Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse
PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)
Time frame: Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse
Participant Psoriasis Area and Severity Index (PASI) score at the conclusion of Part A stratified participants as either Responder (PASI ≥75), Partial Responder (PASI 50 - PASI 74), or Non-Responder (PASI \<50).
| Milestone | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension | Part C: Responder - Low Dose to Placebo | Part C: Responder - Low Dose to ½ Low Dose | Part C: Responder - High Dose to Placebo | Part C: Responder - High Dose to Low Dose | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 34 | 32 | 72 | 64 | 69 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 34 | 32 | 72 | 64 | 69 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 27 | 28 | 67 | 55 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 4 | 5 | 9 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Discontinued at week 12 per protocol | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension | Part C: Responder - Low Dose to Placebo | Part C: Responder - Low Dose to ½ Low Dose | Part C: Responder - High Dose to Placebo | Part C: Responder - High Dose to Low Dose | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 29 | 64 | 19 | 16 | 50 | 43 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 25 | 51 | 13 | 6 | 25 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 4 | 13 | 6 | 10 | 25 | 21 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Completed part b and not moving to partc | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 6 | 8 | 19 | 16 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension | Part C: Responder - Low Dose to Placebo | Part C: Responder - Low Dose to ½ Low Dose | Part C: Responder - High Dose to Placebo | Part C: Responder - High Dose to Low Dose | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 16 | 55 | 55 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 6 | 37 | 18 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 10 | 18 | 37 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Did not qualify for part d per protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 9 | 14 | 34 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension | Part C: Responder - Low Dose to Placebo | Part C: Responder - Low Dose to ½ Low Dose | Part C: Responder - High Dose to Placebo | Part C: Responder - High Dose to Low Dose | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 13 | 19 | 37 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 | 12 | 30 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 7 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.
| Percent of Participants | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI]) | 16.7 | 28.6 | 28.6 | 42.9 | 54.1 |
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.
| Percent of Participants | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA]) | 14.7 | 15.6 | 25.0 | 29.7 | 34.8 |
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.
| Percent of Participants | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA]) | 55.2 | 64.1 | 47.4 | 37.5 | 24.0 | 27.9 | 50.0 |
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.
| Percent of Participants | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|
| Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA]) | 33.3 | 23.1 | 21.1 | 27.0 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.
| Units on a Scale | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI]) | 5.14 ± 1.370 | 9.40 ± 1.413 | 9.46 ± 0.941 | 11.52 ± 0.997 | 13.93 ± 0.962 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.
| Units on a Scale | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI]) | 15.62 ± 5.480 | 16.69 ± 7.399 | 12.94 ± 6.711 | 12.23 ± 7.510 | 14.55 ± 10.493 | 13.67 ± 9.966 | 13.43 ± 5.599 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.
| Units on a Scale | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|
| Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI]) | 6.33 ± 2.836 | 3.25 ± 4.447 | 5.84 ± 5.544 | 6.98 ± 6.456 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12 | -1.7 ± 0.98 | -3.4 ± 1.00 | -4.6 ± 0.67 | -4.0 ± 0.71 | -5.1 ± 0.69 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.
| Units on a Scale | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension |
|---|---|---|---|---|---|---|---|
| Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24 | -6.9 ± 7.53 | -7.0 ± 8.18 | -3.8 ± 6.27 | -1.5 ± 5.92 | -7.8 ± 6.89 | -4.5 ± 8.99 | -3.5 ± 11.76 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.
| Units on a Scale | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|
| Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92 | -3.3 ± 4.93 | -0.5 ± 3.62 | -2.1 ± 7.40 | -5.0 ± 6.31 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12 | -1.1 ± 0.48 | -2.8 ± 0.49 | -3.3 ± 0.33 | -3.8 ± 0.35 | -4.7 ± 0.34 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
| Units on a Scale | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension |
|---|---|---|---|---|---|---|---|
| Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24 | -4.7 ± 3.52 | -5.6 ± 2.96 | -5.4 ± 3.83 | -3.4 ± 3.69 | -4.1 ± 3.33 | -3.5 ± 3.03 | -2.5 ± 4.11 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
| Units on a Scale | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|
| Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92 | -2.3 ± 0.58 | -2.5 ± 3.23 | -2.7 ± 2.91 | -3.1 ± 3.38 |
The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12 | -0.9 ± 0.57 | -1.0 ± 0.58 | -1.0 ± 0.39 | -0.7 ± 0.40 | -0.9 ± 0.40 |
The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.
| Units on a Scale | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension |
|---|---|---|---|---|---|---|---|
| Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24 | -1.6 ± 2.48 | -2.6 ± 3.80 | -1.4 ± 3.15 | -1.2 ± 2.67 | -1.6 ± 2.99 | -2.2 ± 4.64 | -3.0 ± 6.16 |
The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.
| Units on a Scale | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|
| Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92 | — | -0.25 ± 1.708 | -0.13 ± 3.796 | -0.86 ± 2.143 |
The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Millimeter (mm) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg |
|---|---|---|---|---|---|
| Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores | 2.9 ± 2.55 | 5.7 ± 2.46 | 6.4 ± 1.62 | 9.5 ± 1.71 | 7.8 ± 1.69 |
The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.
| mm | Part B: Responder - Low Dose | Part B: Responder - High Dose | Part B: Partial- and Non-responder - Placebo to High Dose | Part B: Partial-responder - Low Dose to Low Dose | Part B: Partial- and Non-responder - Low Dose to High Dose | Part B: Partial- and Non-responder - High Dose to High Dose | Part B: Placebo Extension |
|---|---|---|---|---|---|---|---|
| Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores | 8.1 ± 11.41 | 13.2 ± 22.06 | 9.6 ± 10.78 | 9.4 ± 20.95 | 7.5 ± 14.47 | 10.5 ± 19.94 | 7.8 ± 11.92 |
The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.
| mm | Part D: Baricitinib 2 mg - Retreatment | Part D: Baricitinib 4 mg - Retreatment | Part D: Baricitinib 8 mg - Retreatment | Part D: Baricitinib 10 mg - Retreatment |
|---|---|---|---|---|
| Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores | 8.67 ± 10.263 | 4.00 ± 26.920 | 4.78 ± 13.571 | 4.19 ± 19.727 |
Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score \>125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.
| Percentage of Participants | Part C: Responder - Low Dose to Placebo | Part C: Responder - Low Dose to ½ Low Dose | Part C: Responder - High Dose to Placebo | Part C: Responder - High Dose to Low Dose |
|---|---|---|---|---|
| Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C | 0 | 0 | 0 | 0 |
| nanomole (nM) | Baricitinib 2 mg | Baricitinib 4 mg | Baricitinib 8 mg | Baricitinib 10 mg |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib | 52.4 ± 24.7 | 106 ± 25.9 | 222 ± 24.4 | 260 ± 22.9 |
| nanomole*hour (nM*h) | Baricitinib 2 mg | Baricitinib 4 mg | Baricitinib 8 mg | Baricitinib 10 mg |
|---|---|---|---|---|
| PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss) | 462 ± 40.7 | 975 ± 41.1 | 2030 ± 43.3 | 2440 ± 42.2 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | — | 1/34 (2.9%) | 11/34 (32.4%) |
| Part A: Baricitinib 2 mg | — | 1/32 (3.1%) | 9/32 (28.1%) |
| Part A: Baricitinib 4 mg | — | 1/72 (1.4%) | 12/72 (16.7%) |
| Part A: Baricitinib 8 mg | — | 1/64 (1.6%) | 21/64 (32.8%) |
| Part A: Baricitinib 10 mg | — | 1/69 (1.4%) | 23/69 (33.3%) |
| Part B: Placebo | — | 0/8 (0%) | 4/8 (50%) |
| Part B: Low Dose | — | 0/45 (0%) | 13/45 (28.9%) |
| Part B: High Dose | — | 2/176 (1.1%) | 41/176 (23.3%) |
| Part C: Placebo | — | 1/70 (1.4%) | 11/70 (15.7%) |
| Part C: Baricitinib | — | 1/71 (1.4%) | 16/71 (22.5%) |
| Part D: All Baricitinib Doses | — | 1/72 (1.4%) | 37/72 (51.4%) |
| Follow-up: Always Placebo | — | 0/8 (0%) | 0/8 (0%) |
| Follow-up: Ever Used Baricitinib | — | 0/185 (0%) | 8/185 (4.3%) |
| Event | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Part B: Placebo | Part B: Low Dose | Part B: High Dose | Part C: Placebo | Part C: Baricitinib | Part D: All Baricitinib Doses | Follow-up: Always Placebo | Follow-up: Ever Used Baricitinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovarian adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 0/176 | 0/70 | 1/17 | 0/72 | 0/8 | 0/185 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/34 | 1/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Diabetic footSkin and subcutaneous tissue disorders | 1/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 0/32 | 0/72 | 1/64 | 0/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| PneumoniaInfections and infestations | 0/34 | 0/32 | 0/72 | 0/64 | 1/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| CellulitisInfections and infestations | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 0/176 | 1/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 1/72 | 0/8 | 0/185 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 0/32 | 1/72 | 0/64 | 0/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 1/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 0/45 | 1/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Event | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Part B: Placebo | Part B: Low Dose | Part B: High Dose | Part C: Placebo | Part C: Baricitinib | Part D: All Baricitinib Doses | Follow-up: Always Placebo | Follow-up: Ever Used Baricitinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/34 | 1/32 | 2/72 | 6/64 | 6/69 | 0/8 | 5/45 | 9/176 | 3/70 | 6/71 | 12/72 | 0/8 | 2/185 |
| Gastric ulcerGastrointestinal disorders | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 1/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Muscle strainInjury, poisoning and procedural complications | 0/34 | 0/32 | 0/72 | 1/64 | 0/69 | 1/8 | 0/45 | 2/176 | 0/70 | 0/71 | 2/72 | 0/8 | 0/185 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/34 | 0/32 | 0/72 | 0/64 | 1/69 | 1/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| HeadacheNervous system disorders | 2/34 | 0/32 | 3/72 | 5/64 | 1/69 | 1/8 | 3/45 | 7/176 | 1/70 | 1/71 | 1/72 | 0/8 | 0/185 |
| Upper respiratory tract infectionInfections and infestations | 1/34 | 1/32 | 0/72 | 1/64 | 2/69 | 0/8 | 2/45 | 5/176 | 0/70 | 1/71 | 7/72 | 0/8 | 1/185 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/34 | 0/32 | 0/72 | 0/64 | 0/69 | 0/8 | 1/13 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| Blood creatine phosphokinase increasedInvestigations | 0/34 | 2/32 | 1/72 | 3/64 | 5/69 | 0/8 | 0/45 | 1/176 | 0/70 | 1/71 | 3/72 | 0/8 | 1/185 |
| Abdominal discomfortGastrointestinal disorders | 1/34 | 2/32 | 0/72 | 2/64 | 2/69 | 0/8 | 0/45 | 0/176 | 0/70 | 0/71 | 0/72 | 0/8 | 0/185 |
| FatigueGeneral disorders | 1/34 | 2/32 | 0/72 | 1/64 | 0/69 | 0/8 | 0/45 | 1/176 | 0/70 | 0/71 | 1/72 | 0/8 | 0/185 |
All randomized participants who received at least one dose of study drug.
| Age, Customized(Years) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 46.70 ± 15.144 | 47.81 ± 15.165 | 47.21 ± 11.650 | 47.37 ± 15.829 | 47.43 ± 10.425 | 47.31 ± 13.268 |
| Sex/Gender, Customized(Participants) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 9 | 18 | 18 | 18 | 74 |
| Male | 23 | 23 | 54 | 46 | 51 | 197 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 11 | 12 | 10 | 43 |
| Not Hispanic or Latino | 30 | 26 | 61 | 52 | 59 | 228 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 7 | 6 | 12 | 9 | 11 | 45 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 1 | 4 | 7 |
| White | 26 | 26 | 58 | 52 | 53 | 215 |
| More than one race | 0 | 0 | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Japan | 4 | 4 | 9 | 8 | 8 | 33 |
| North America | 30 | 28 | 63 | 56 | 61 | 238 |
| Duration of Psoriasis (Ps)(Years) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 16.42 ± 14.297 | 15.00 ± 9.951 | 19.90 ± 12.766 | 16.56 ± 11.948 | 16.60 ± 10.653 | 17.26 ± 11.995 |
| Percent Body Surface Area (BSA) Affected by Psoriasis(Percent of BSA) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 23.18 ± 11.890 | 30.78 ± 20.523 | 28.61 ± 18.797 | 28.23 ± 15.726 | 24.45 ± 12.079 | 27.04 ± 16.101 |
| Baseline Psoriasis Area and Severity Index (PASI) Score(Units on a Scale) | Part A: Placebo | Part A: Baricitinib 2 mg | Part A: Baricitinib 4 mg | Part A: Baricitinib 8 mg | Part A: Baricitinib 10 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 19.06 ± 6.805 | 21.36 ± 11.056 | 20.58 ± 9.438 | 20.24 ± 7.827 | 19.01 ± 6.177 | 20.00 ± 8.228 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Dec 2011, a primary completion of Dec 2012 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 4 years 7 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib